Opportunities and strategies for breast cancer prevention through risk reduction

CA Cancer Journal for Clinicians

Volumn 58, Issue 6, 2008, Pages 347-371

  Mahoney, Martin C ^a   Bevers, Therese ^b   Linos, Eleni ^c   Willett, Walter C ^d  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CELECOXIB; ESTROGEN; EXEMESTANE; FOLIC ACID; GONADORELIN AGONIST; GREEN TEA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOFLAVONE DERIVATIVE; LETROZOLE; MEDROXYPROGESTERONE ACETATE; NOLVALDEX; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTOESTROGEN; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RALOXIFENE; RETINOID DERIVATIVE; ROFECOXIB; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN CITRATE; TRACE ELEMENT; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ALCOHOL CONSUMPTION; ARTHROPATHY; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CARBOHYDRATE INTAKE; CARDIOVASCULAR RISK; CATARACT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DIET THERAPY; DIETARY INTAKE; DRUG USE; DYSPAREUNIA; ENDOMETRIUM CANCER; FAT INTAKE; FRACTURE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LEG CRAMP; LIFESTYLE; LUNG EMBOLISM; MAMMOGRAPHY; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; URINE INCONTINENCE; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINA PAIN; VAGINAL DRYNESS; VAGINAL PRURITUS; WEIGHT GAIN;

BREAST NEOPLASMS; FEMALE; HUMANS; INCIDENCE; NEOPLASM RECURRENCE, LOCAL; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; UNITED STATES;

EID: 55849103179     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/CA.2008.0016     Document Type: Review

References (163)

1. National Cancer Institute, US National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use, Nov 2006 Sub (1973-2004 varying), Linked to County Attributes, Total US, 1969-2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
2. American Cancer Society. Cancer Facts & Figures 2008. Atlanta, GA: American Cancer Society; 2008.
3. National Cancer Institute, US National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) .
4. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006;56:168-183.
5. American Cancer Society. Breast Cancer Facts and Figures 2005-2006. Atlanta, GA: American Cancer Society; 2005.
6. National Cancer Institute, US National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) DevCan Database: SEER 17 Incidence and Mortality, 2000-2003, with Kaposi Sarcoma and Mesothelioma. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.
7. National Cancer Institute, US National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) DevCan Database: SEER 17 Incidence and Mortality, 2000-2003, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.
8. National Center for Health Statistics. Health, United States, 2006 with Chartbook on Trends in the Health of Americans. Hyattsville, MD: National Center for Health Statistics; 2006.
9. Centers for Disease Control and Prevention. Use of mammograms among women aged > or = 40 years - United States, 2000-2005. MMWR Morb Mortal Wkly Rep 2007;56:49-51.
10. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. CA Cancer J Clin 2008;58:161-179.
11. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89.
12. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003;21:2397-2406.
13. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Available at: http://www.nccn.org/professionals/ physician_gls/PDF/genetics_screening.pdf. Accessed July 18, 2008.
14. Nelson HD, Huffman LH, Fu R, Harris EL. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2005;143:362-379.
15. Singletary SE. Rating the risk factors for breast cancer. Ann Surg 2003;237:474-482.
16. Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 2007;96:11-15.
17. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002;360:187-195.
18. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97:1428-1437.
19. Ursin G, Ma H, Wu AH,et al. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 2003;12:332-338.
20. Monninkhof EM, Elias SG, Vlems FA, et al. Physical activity and breast cancer: a systematic review. Epidemiology 2007;18:137-157.
21. Whittemore AS, Gong G, John EM, et al. Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev 2004;13:2078-2083.
22. Nusbaum R, Vogel KJ, Ready K. Susceptibility to breast cancer: hereditary syndromes and low penetrance genes. Breast Dis 2006;27:21-50.
23. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745-751.
24. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993;85:25-31.
25. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465-475.
26. Children's Oncology Group. Long-term Follow-up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Bethesda, MD: Children's Oncology Group; 2006.
27. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886.
28. Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 2007;99:1782-1792.
29. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991;48:232-242.
30. van Asperen CJ, Jonker MA, Jacobi CE, et al. Risk estimation for healthy women from breast cancer families: new insights and new strategies. Cancer Epidemiol Biomarkers Prev 2004;13:87-93.
31. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145-158.
32. Chen J, Pee D, Ayyagari R, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 2006;98:1215-1226.
33. Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 2006;98:1204-1214.
34. Amir E, Evans DG, Shenton A, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 2003;40:807-814.
35. Evans DG, Howell A. Breast cancer risk-assessment models. Breast Cancer Res 2007;9:213.
36. Jordan VC. Selective estrogen receptor modulation: a personal perspective. Cancer Res 2001;61:5683-5687.
37. Fisher B, Redmond C. New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J Natl Cancer Inst 1991;83:1278-1280.
38. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-1467.
39. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
40. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-1662.
41. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93-97.
42. Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007;99:727-737.
43. Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95:160-165.
44. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
45. Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007;99:283-290.
46. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-824.
47. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272-282.
48. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
49. Day R, Ganz PA, Costantino JP, et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999;17:2659-2669.
50. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137.
51. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-134.
52. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197.
53. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-645.
54. Lamb CA, Helguero LA, Fabris V, et al. Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma. Breast Cancer Res Treat 2003;79:25-35.
55. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-1761.
56. Sporn MB, Dowsett SA, Mershon J, Bryant HU. Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clin Ther 2004;26:830-840.
57. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
58. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2742-2751.
59. Ganz PA, Gotay CC. Use of patient-reported outcomes in phase III cancer treatment trials: lessons learned and future directions. J Clin Oncol 2007;25:5063-5069.
60. Kaplan CP, Haas JS, Pérez-Stable EJ, et al. Factors affecting breast cancer risk reduction practices among California physicians. Prev Med 2005;41:7-15.
61. Bevers TB. Raloxifene and the prevention of breast cancer. Expert Opin Pharmacother 2006;7:2301-2307.
62. Armstrong K, Quistberg DA, Micco E, et al. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med 2006;166:2260-2265.
63. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-1846.
64. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-532.
65. Boccardo F, Rubagotti A, Guglielmini P, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006;17(suppl):vii10- vii14.
66. Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-492.
67. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years'tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559-570.
68. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802.
69. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
70. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092.
71. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-2139.
72. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol;2005;23:1636-1643.
73. Goss PE, Strasser-Weippl K. Prevention strategies with aromatase inhibitors. Clin Cancer Res 2004;10:372S-379S.
74. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.
75. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005l;352:1071-1080.
76. Moorman PG, Grubber JM, Millikan RC, Newman B. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 2003;14:915-922.
77. Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk. Oncology 2005;68:40-47.
78. Egan KM, Stampfer MJ, Giovannucci E, et al. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 1996;88:988-993.
79. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55.
80. Fabian CJ. Breast cancer chemoprevention: beyond tamoxifen. Breast Cancer Res 2001;3:99-103.
81. Howell A, Sims AH, Ong KR, et al. Mechanisms of Disease: prediction and prevention of breast cancer - cellular and molecular interactions. Nat Clin Pract Oncol 2005;2:635-646.
82. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-1059.
83. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-1045.
84. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
85. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027-1032.
86. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 2000;152:950-964.
87. World Cancer Research Fund and American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective 2007. Washington, DC: World Cancer Research Fund and American Institute for Cancer Research; 2007.
88. Michels KB, Mohllajee AP, Roset-Bahmanyar E, et al. Diet and breast cancer: a review of the prospective observational studies. Cancer 2007;109(suppl):2712-2749.
89. Linos E, Willett WC. Diet and breast cancer risk reduction. J Natl Compr Canc Netw 2007;5:711-718.
90. Boyd NF, Stone J, Vogt KN, et al. Dietary fat and breast cancer risk revisited: a meta-analysis of the published literature. Br J Cancer 2003;89:1672-1685.
91. Smith-Warner SA, Spiegelman D, Adami HO, et al. Types of dietary fat and breast cancer: a pooled analysis of cohort studies. Int J Cancer 2001;92:767-774.
92. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006;295:629-642.
93. Thiébaut AC, Kipnis V, Chang SC, et al. Dietary fat and postmenopausal invasive breast cancer in the National Institutes of Health-AARP Diet and Health Study cohort. J Natl Cancer Inst 2007;99:451-462.
94. Sieri S, Pala V, Brighenti F, et al. Dietary glycemic index, glycemic load, and the risk of breast cancer in an Italian prospective cohort study. Am J Clin Nutr 2007;86:1160-1166.
95. Missmer SA, Smith-Warner SA, Spiegelman D, et al. Meat and dairy food consumption and breast cancer: a pooled analysis of cohort studies. Int J Epidemiol 2002;31:78-85.
96. Cho E, Chen WY, Hunter DJ, et al. Red meat intake and risk of breast cancer among premenopausal women. Arch Intern Med 2006;166:2253-2259.
97. Taylor EF, Burley VJ, Greenwood DC, Cade JE. Meat consumption and risk of breast cancer in the UK Women's Cohort Study. Br J Cancer 2007;96:1139-1146.
98. Egeberg R, Olsen A, Autrup H, et al. Meat consumption, N-acetyl transferase 1 and 2 polymorphism and risk of breast cancer in Danish postmenopausal women. Eur J Cancer Prev 2008;17:39-47.
99. Pierce JP, Natarajan L, Caan BJ, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 2007;298:289-298.
100. Larsson SC, Giovannucci E, Wolk A. Folate and risk of breast cancer: a meta-analysis. J Natl Cancer Inst 2007;99:64-76.
101. Lewis SJ, Harbord RM, Harris R, Smith GD. Meta-analyses of observational and genetic association studies of folate intakes or levels and breast cancer risk. J Natl Cancer Inst 2006;98:1607-1622.
102. Shin MH, Holmes MD, Hankinson SE, et al. Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst 2002;94:1301-1311.
103. Bertone-Johnson ER, Chen WY, Holick MF, et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1991-1997.
104. Michels KB, Holmberg L, Bergkvist L, Wolk A. Coffee, tea, and caffeine consumption and breast cancer incidence in a cohort of Swedish women. Ann Epidemiol 2002;12:21-26.
105. Tamimi RM, Hankinson SE, Campos H, et al. Plasma carotenoids, retinol, and tocopherols and risk of breast cancer. Am J Epidemiol 2005;161:153-160.
106. Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 2006;98:459-471.
107. Duffy C, Perez K, Partridge A. Implications of phytoestrogen intake for breast cancer. CA Cancer J Clin 2007;57:260-277.
108. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 1998;279:535-540.
109. Hamajima N, Hirose K, Tajima K, et al. Alcohol, tobacco and breast cancer - collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002;87:1234-1245.
110. Chen WY, Willett WC, Rosner B, Coldtiz GA. Moderate alcohol consumption and breast cancer [abstract]. J Clin Oncol 2005;23(suppl):7s. Abstract 515.
111. Zhang SM, Lee IM, Manson JE, et al. Alcohol consumption and breast cancer risk in the Women's Health Study. Am J Epidemiol 2007;165:667-676.
112. Zhang SM, Willett WC, Selhub J, et al. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst 2003;95:373-380.
113. Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999;281:1632-1637.
114. Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 1982;2:5-73.
115. Ariazi JL, Haag JD, Lindstrom MJ, Gould MN. Mammary glands of sexually immature rats are more susceptible than those of mature rats to the carcinogenic, lethal, and mutagenic effects of N-nitroso-N-methylurea. Mol Carcinog 2005;43:155-164.
116. Land CE. Studies of cancer and radiation dose among atomic bomb survivors. The example of breast cancer. JAMA 1995;274:402-407.
117. Land CE, Tokunaga M, Koyama K, et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiat Res 2003;160:707-717.
118. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 1993;85:1819-1827.
119. Tretli S, Gaard M. Lifestyle changes during adolescence and risk of breast cancer: an ecologic study of the effect of World War II in Norway. Cancer Causes Control 1996;7:507-512.
120. Pryor M, Slattery ML, Robison LM, Egger M. Adolescent diet and breast cancer in Utah. Cancer Res 1989;49:2161-2167.
121. Knight JA, Lesosky M, Barnett H, et al. Vitamin D and reduced risk of breast cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007;16:422-429.
122. Hislop TG, Coldman AJ, Elwood JM, et al. Childhood and recent eating patterns and risk of breast cancer. Cancer Detect Prev 1986;9:47-58.
123. Potischman N, Weiss HA, Swanson CA, et al. Diet during adolescence and risk of breast cancer among young women. J Natl Cancer Inst 1998;90:226-233.
124. Maruti SS, Feskanich D, Rockett HR, et al. Validation of adolescent diet recalled by adults. Epidemiology 2006;17:226-229.
125. Maruti SS, Feskanich D, Colditz GA, et al. Adult recall of adolescent diet: reproducibility and comparison with maternal reporting. Am J Epidemiol 2005;161:89-97.
126. Frazier AL, Li L, Cho E, et al. Adolescent diet and risk of breast cancer. Cancer Causes Control 2004;15:73-82.
127. Wu AH, Wan P, Hankin J, et al. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 2002;23:1491-1496.
128. Shu XO, Jin F, Dai Q, et al. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 2001;10:483-488.
129. Thanos J, Cotterchio M, Boucher BA, et al. Adolescent dietary phytoestrogen intake and breast cancer risk (Canada). Cancer Causes Control 2006;17:1253-1261.
130. Tretli S. Height and weight in relation to breast cancer morbidity and mortality. A prospective study of 570,000 women in Norway. Int J Cancer 1989;44:23-30.
131. Cho E, Spiegelman D, Hunter DJ, et al. Premenopausal fat intake and risk of breast cancer. J Natl Cancer Inst 2003;95:1079-1085.
132. Holmes MD, Liu S, Hankinson SE, et al. Dietary carbohydrates, fiber, and breast cancer risk. Am J Epidemiol 2004;159:732-739.
133. Higginbotham S, Zhang ZF, Lee IM, et al. Dietary glycemic load and breast cancer risk in the Women's Health Study. Cancer Epidemiol Biomarkers Prev 2004;13:65-70.
134. Jonas CR, McCullough ML, Teras LR, et al. Dietary glycemic index, glycemic load, and risk of incident breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2003;12:573-577.
135. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA 2001;285:769-776.
136. Holmes MD, Willett WC. Does diet affect breast cancer risk? Breast Cancer Res 2004;6:170-178.
137. Zhang S, Hunter DJ, Forman MR, et al. Dietary carotenoids and vitamins A,C, and E and risk of breast cancer. J Natl Cancer Inst 1999;91:547-556.
138. Hankinson SE, Willett WC, Manson JE, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995;87:1297-1302.
139. Newcomb PA, Klein R, Klein BE, et al. Association of dietary and life-style factors with sex hormones in postmenopausal women. Epidemiology 1995;6:318-321.
140. Thomas HV, Reeves GK, Key TJ. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 1997;8:922-928.
141. Key TJ, Verkasalo PK. Endogenous hormones and the aetiology of breast cancer. Breast Cancer Res 1999;1:18-21.
142. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height,weight, and breast cancer risk. Am J Epidemiol 2000;152:514-527.
143. Radimer KL, Ballard-Barbash R, Miller JS, et al. Weight change and the risk of late-onset breast cancer in the original Framingham cohort. Nutr Cancer 2004;49:7-13.
144. Ahn J, Schatzkin A, Lacey JV Jr, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med 2007;167:2091-2102.
145. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 2004;111:762-771.
146. Eliassen AH, Tworoger SS, Mantzoros CS, et al. Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev 2007;16:161-164.
147. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 1997;278:1407-1411.
148. Enriori CL, Orsini W, del Carmen Cremona M,et al. Decrease of circulating level of SHBG in postmenopausal obese women as a risk factor in breast cancer: reversible effect of weight loss. Gynecol Oncol 1986;23:77-86.
149. de Waard F, Poortman J, de Pedro-Alvarez Ferrero M, Baanders-van Halewijn EA. Weight reduction and oestrogen excretion in obese postmenopausal women. Maturitas 1982;4:155-162.
150. Harvie M, Howell A, Vierkant RA, et al. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 2005;14:656-661.
151. Schernhammer ES, Tworoger SS, Eliassen AH, et al. Body shape throughout life and correlations with IGFs and GH. Endocr Relat Cancer 2007;14:721-732.
152. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
153. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001;93:1633-1637.
154. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-1622.
155. Breast Cancer Risk Reduction 2007. Jenkintown, PA: National Comprehensive Cancer Network; 2007. Available at http://www.nccn.org/professionals/ physician_gls/PDF/breast_risk.pdf. Accessed on August 24, 2008.
156. Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006;24:4642-4660.
157. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332.
158. Feigelson HS, Patel AV, Teras LR, et al. Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women. Cancer 2006;107:12-21.
159. Feigelson HS, Jonas CR, Teras LR, et al. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2004;13:220-224.
160. Morimoto LM, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002;13:741-751.
161. Eliassen AH, Colditz GA, Rosner B, et al. Adult weight change and risk of postmenopausal breast cancer. JAMA 2006;296:193-201.
162. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 2002;132(suppl):3456S- 3464S.
163. Irwin ML. Randomized controlled trials of physical activity and breast cancer prevention. Exerc Sport Sci Rev 2006;34:182-193.